GlassScriptPhysician profile
Lyeba Shahid
NPI 1427790542
$414.07
in general payments reported to CMS, 2019-2025
9 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $105.55 | 2025 | Trodelvy |
| Pfizer INC. | $64.73 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $50.41 | 2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $38.99 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.63 | 2025 | Jardiance |
| Novo Nordisk INC | $36.46 | 2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $32.23 | 2025 | |
| Sumitomo Pharma America, INC. | $29.74 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $19.33 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyeba Shahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.